New oral protease-activated receptor 4 antagonist BMS-986120: tolerability, pharmacokinetics, pharmacodynamics, and gene variant effects in humans

New oral protease-activated receptor 4 antagonist BMS-986120: tolerability, pharmacokinetics, pharmacodynamics, and gene variant effects in humans

BMS-986120 is a novel first-in-class oral protease-activated receptor 4 (PAR4) antagonist exhibiting robust antithrombotic activity that has shown low bleeding risk in monkeys. We sought to assess pharmacokinetics, pharmacodynamics, and tolerability of BMS-986120 in healthy participants and platelet...

Full description

Bibliographic Details
Main Authors: Samira Merali, Zhaoqing Wang, Charles Frost, Mario Callejo, Michael Hedrick, Lester Hui, Stephanie Meadows Shropshire, Ke Xu, Michel Bouvier, Mary M. DeSouza, Jing Yang
Format: Article
Language:English
Published: Taylor & Francis Group 2022-10-01
Series:Platelets
Subjects:
antiplatelet
pharmacokinetics
clinical trial
platelet
Online Access:http://dx.doi.org/10.1080/09537104.2022.2088719

Internet

http://dx.doi.org/10.1080/09537104.2022.2088719

Similar Items